RESTON, VA - A novel positron emission tomography (PET) imaging method shows promise for noninvasively pinpointing sites of inflammation in people with inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease. The University of California, Los Angeles (UCLA), study is featured in the June issue of The Journal of Nuclear Medicine.
The U.S. Centers for Disease Control states that approximately three million Americans reported being diagnosed with IBD in 2015 (latest data). Managing patients with chronic bowel inflammation can be challenging, relying on symptoms and invasive procedures such as colonoscopy and biopsy.
In a mouse model of colitis, this study uses PET imaging with antibody fragment probes (immunoPET) to target a specific subset of immune cells, the CD4+ T cells, which are characteristic of IBD.
"CD4 immunoPET could provide a noninvasive means to detect and localize sites of inflammation in the bowel and also provide image guidance for biopsies if needed," explains Anna M. Wu, PhD, professor of Molecular and Medical Pharmacology at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging Program, who headed the project and collaborated with Jonathan Braun, MD, and Arion Chatziioannou, PhD, also of UCLA. She adds, "Assessment of CD4 infiltration could also potentially provide a means for detection of subclinical disease, before symptoms occur, and provide a readout as to the efficacy of therapeutic interventions."
A zirconium-89 (89Zr)-labeled anti-CD4 engineered antibody fragment [GK1.5 cDb] was used for noninvasive imaging of the distribution of CD4+ T cells in the mice with induced colitis, and it successfully detected CD4+ T cells in the colon, ceca and mesenteric lymph nodes. The study demonstrates that CD4 immunoPET of IBD warrants further investigation and has the potential to guide development of antibody-based imaging in humans with IBD.
Wu points out that the ability to directly image immune responses could have wide applications, saying, "It could unlock our ability to assess inflammation in a broad spectrum of disease areas, including oncology and immune-oncology, auto-immunity, cardiovascular disease, neuroinflammation, and more. ImmunoPET is a robust and general platform for visualization of highly specific molecular targets."
Authors of "ImmunoPET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis" include Amanda C. Freise, Kirstin A. Zettlitz, Felix B. Salazar, Wen-Ting K. Tsai, Arion F. Chatziioannou, Nora Rozengurt, Jonathan Braun, and Anna M. Wu, UCLA, Los Angeles, California, and Richard Tavaré, UCLA and now Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.
ABOUT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI's more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.